Limitations, agreements, and source contact

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma · Source last updated 2013-11-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

irene_ghobrial@dfci.harvard.edu

organization

Dana-Farber Cancer Institute

phone

617-632-4198

title

Irene Ghobrial, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice